nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR3—urinary bladder cancer	0.339	0.664	CbGaD
Ponatinib—SRC—urinary bladder cancer	0.171	0.336	CbGaD
Ponatinib—ABCB1—Mitomycin—urinary bladder cancer	0.026	0.127	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—urinary bladder cancer	0.0213	0.104	CbGbCtD
Ponatinib—ABCG2—Fluorouracil—urinary bladder cancer	0.0178	0.087	CbGbCtD
Ponatinib—ABCG2—Carboplatin—urinary bladder cancer	0.0176	0.0865	CbGbCtD
Ponatinib—ABCG2—Cisplatin—urinary bladder cancer	0.0151	0.0739	CbGbCtD
Ponatinib—ABCG2—Etoposide—urinary bladder cancer	0.0148	0.0726	CbGbCtD
Ponatinib—CYP3A4—Thiotepa—urinary bladder cancer	0.0118	0.0578	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—urinary bladder cancer	0.0101	0.0495	CbGbCtD
Ponatinib—ABCG2—Methotrexate—urinary bladder cancer	0.00979	0.048	CbGbCtD
Ponatinib—CYP2C8—Fluorouracil—urinary bladder cancer	0.00946	0.0463	CbGbCtD
Ponatinib—CYP3A5—Etoposide—urinary bladder cancer	0.00821	0.0402	CbGbCtD
Ponatinib—CYP2C8—Etoposide—urinary bladder cancer	0.00789	0.0387	CbGbCtD
Ponatinib—ABCB1—Gemcitabine—urinary bladder cancer	0.00748	0.0367	CbGbCtD
Ponatinib—ABCB1—Cisplatin—urinary bladder cancer	0.00544	0.0266	CbGbCtD
Ponatinib—ABCB1—Etoposide—urinary bladder cancer	0.00534	0.0262	CbGbCtD
Ponatinib—ABCB1—Doxorubicin—urinary bladder cancer	0.00364	0.0179	CbGbCtD
Ponatinib—PDGFRA—penis—urinary bladder cancer	0.00364	0.0553	CbGeAlD
Ponatinib—ABCB1—Methotrexate—urinary bladder cancer	0.00353	0.0173	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—urinary bladder cancer	0.00343	0.0168	CbGbCtD
Ponatinib—CYP3A4—Etoposide—urinary bladder cancer	0.0032	0.0157	CbGbCtD
Ponatinib—KDR—umbilical vein—urinary bladder cancer	0.00271	0.0411	CbGeAlD
Ponatinib—FGFR4—prostate gland—urinary bladder cancer	0.00224	0.034	CbGeAlD
Ponatinib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00218	0.0107	CbGbCtD
Ponatinib—FGFR3—prostate gland—urinary bladder cancer	0.00153	0.0232	CbGeAlD
Ponatinib—FGFR4—renal system—urinary bladder cancer	0.00153	0.0232	CbGeAlD
Ponatinib—BCR—prostate gland—urinary bladder cancer	0.00132	0.0201	CbGeAlD
Ponatinib—FGFR4—female reproductive system—urinary bladder cancer	0.00122	0.0186	CbGeAlD
Ponatinib—FGFR1—prostate gland—urinary bladder cancer	0.00118	0.0179	CbGeAlD
Ponatinib—FGFR3—epithelium—urinary bladder cancer	0.00112	0.0171	CbGeAlD
Ponatinib—BCR—seminal vesicle—urinary bladder cancer	0.00112	0.017	CbGeAlD
Ponatinib—LCK—prostate gland—urinary bladder cancer	0.00105	0.016	CbGeAlD
Ponatinib—RET—prostate gland—urinary bladder cancer	0.00105	0.016	CbGeAlD
Ponatinib—FGFR3—renal system—urinary bladder cancer	0.00104	0.0158	CbGeAlD
Ponatinib—FGFR3—urethra—urinary bladder cancer	0.00102	0.0155	CbGeAlD
Ponatinib—FGFR2—prostate gland—urinary bladder cancer	0.001	0.0152	CbGeAlD
Ponatinib—TEK—prostate gland—urinary bladder cancer	0.000961	0.0146	CbGeAlD
Ponatinib—FGFR4—Podofilox—Etoposide—urinary bladder cancer	0.000957	0.318	CbGdCrCtD
Ponatinib—BCR—renal system—urinary bladder cancer	0.000903	0.0137	CbGeAlD
Ponatinib—BCR—urethra—urinary bladder cancer	0.000887	0.0134	CbGeAlD
Ponatinib—PDGFRA—prostate gland—urinary bladder cancer	0.00087	0.0132	CbGeAlD
Ponatinib—SRC—prostate gland—urinary bladder cancer	0.000854	0.0129	CbGeAlD
Ponatinib—FGFR3—female reproductive system—urinary bladder cancer	0.000836	0.0127	CbGeAlD
Ponatinib—FGFR1—urethra—urinary bladder cancer	0.000789	0.012	CbGeAlD
Ponatinib—KDR—prostate gland—urinary bladder cancer	0.000785	0.0119	CbGeAlD
Ponatinib—RET—epithelium—urinary bladder cancer	0.000775	0.0118	CbGeAlD
Ponatinib—CYP3A4—urine—urinary bladder cancer	0.000741	0.0112	CbGeAlD
Ponatinib—FGFR2—epithelium—urinary bladder cancer	0.000736	0.0112	CbGeAlD
Ponatinib—CYP2D6—urine—urinary bladder cancer	0.000729	0.0111	CbGeAlD
Ponatinib—BCR—female reproductive system—urinary bladder cancer	0.000723	0.011	CbGeAlD
Ponatinib—RET—renal system—urinary bladder cancer	0.000719	0.0109	CbGeAlD
Ponatinib—FLT3—female reproductive system—urinary bladder cancer	0.000718	0.0109	CbGeAlD
Ponatinib—FGFR4—lymph node—urinary bladder cancer	0.000716	0.0109	CbGeAlD
Ponatinib—FGFR2—smooth muscle tissue—urinary bladder cancer	0.00071	0.0108	CbGeAlD
Ponatinib—LCK—urethra—urinary bladder cancer	0.000706	0.0107	CbGeAlD
Ponatinib—TEK—epithelium—urinary bladder cancer	0.000706	0.0107	CbGeAlD
Ponatinib—KIT—prostate gland—urinary bladder cancer	0.000696	0.0106	CbGeAlD
Ponatinib—FGFR2—renal system—urinary bladder cancer	0.000683	0.0104	CbGeAlD
Ponatinib—TEK—smooth muscle tissue—urinary bladder cancer	0.00068	0.0103	CbGeAlD
Ponatinib—KDR—seminal vesicle—urinary bladder cancer	0.000664	0.0101	CbGeAlD
Ponatinib—TEK—renal system—urinary bladder cancer	0.000655	0.00993	CbGeAlD
Ponatinib—BCR—vagina—urinary bladder cancer	0.000654	0.00992	CbGeAlD
Ponatinib—TEK—urethra—urinary bladder cancer	0.000643	0.00975	CbGeAlD
Ponatinib—SRC—epithelium—urinary bladder cancer	0.000627	0.00951	CbGeAlD
Ponatinib—PDGFRA—smooth muscle tissue—urinary bladder cancer	0.000616	0.00935	CbGeAlD
Ponatinib—ABL1—prostate gland—urinary bladder cancer	0.000606	0.00919	CbGeAlD
Ponatinib—SRC—smooth muscle tissue—urinary bladder cancer	0.000604	0.00916	CbGeAlD
Ponatinib—PDGFRA—renal system—urinary bladder cancer	0.000593	0.009	CbGeAlD
Ponatinib—KIT—seminal vesicle—urinary bladder cancer	0.000589	0.00892	CbGeAlD
Ponatinib—FGFR1—vagina—urinary bladder cancer	0.000582	0.00882	CbGeAlD
Ponatinib—SRC—renal system—urinary bladder cancer	0.000582	0.00882	CbGeAlD
Ponatinib—KDR—epithelium—urinary bladder cancer	0.000577	0.00875	CbGeAlD
Ponatinib—KDR—smooth muscle tissue—urinary bladder cancer	0.000556	0.00843	CbGeAlD
Ponatinib—FGFR2—female reproductive system—urinary bladder cancer	0.000547	0.00829	CbGeAlD
Ponatinib—KDR—renal system—urinary bladder cancer	0.000535	0.00812	CbGeAlD
Ponatinib—KDR—urethra—urinary bladder cancer	0.000526	0.00797	CbGeAlD
Ponatinib—TEK—female reproductive system—urinary bladder cancer	0.000524	0.00795	CbGeAlD
Ponatinib—LCK—vagina—urinary bladder cancer	0.000521	0.0079	CbGeAlD
Ponatinib—ABL1—seminal vesicle—urinary bladder cancer	0.000512	0.00777	CbGeAlD
Ponatinib—KIT—epithelium—urinary bladder cancer	0.000511	0.00775	CbGeAlD
Ponatinib—KIT—smooth muscle tissue—urinary bladder cancer	0.000493	0.00747	CbGeAlD
Ponatinib—PDGFRA—female reproductive system—urinary bladder cancer	0.000475	0.0072	CbGeAlD
Ponatinib—KIT—renal system—urinary bladder cancer	0.000474	0.00719	CbGeAlD
Ponatinib—SRC—female reproductive system—urinary bladder cancer	0.000466	0.00707	CbGeAlD
Ponatinib—KIT—urethra—urinary bladder cancer	0.000466	0.00706	CbGeAlD
Ponatinib—PDGFRA—vagina—urinary bladder cancer	0.00043	0.00652	CbGeAlD
Ponatinib—ABL1—smooth muscle tissue—urinary bladder cancer	0.000429	0.0065	CbGeAlD
Ponatinib—KDR—female reproductive system—urinary bladder cancer	0.000429	0.0065	CbGeAlD
Ponatinib—BCR—lymph node—urinary bladder cancer	0.000423	0.00641	CbGeAlD
Ponatinib—FLT3—lymph node—urinary bladder cancer	0.00042	0.00637	CbGeAlD
Ponatinib—ABL1—renal system—urinary bladder cancer	0.000413	0.00626	CbGeAlD
Ponatinib—ABL1—urethra—urinary bladder cancer	0.000406	0.00615	CbGeAlD
Ponatinib—KDR—vagina—urinary bladder cancer	0.000388	0.00588	CbGeAlD
Ponatinib—ABCG2—prostate gland—urinary bladder cancer	0.000382	0.00579	CbGeAlD
Ponatinib—KIT—female reproductive system—urinary bladder cancer	0.00038	0.00576	CbGeAlD
Ponatinib—FGFR1—lymph node—urinary bladder cancer	0.000376	0.00571	CbGeAlD
Ponatinib—CYP3A5—prostate gland—urinary bladder cancer	0.000355	0.00538	CbGeAlD
Ponatinib—KIT—vagina—urinary bladder cancer	0.000344	0.00521	CbGeAlD
Ponatinib—ABL1—Daunorubicin—Valrubicin—urinary bladder cancer	0.000342	0.114	CbGdCrCtD
Ponatinib—ABL1—Doxorubicin—Valrubicin—urinary bladder cancer	0.000342	0.114	CbGdCrCtD
Ponatinib—ABL1—Epirubicin—Valrubicin—urinary bladder cancer	0.000342	0.114	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Valrubicin—urinary bladder cancer	0.000342	0.114	CbGdCrCtD
Ponatinib—RET—lymph node—urinary bladder cancer	0.000337	0.00511	CbGeAlD
Ponatinib—LCK—lymph node—urinary bladder cancer	0.000337	0.00511	CbGeAlD
Ponatinib—ABL1—female reproductive system—urinary bladder cancer	0.000331	0.00501	CbGeAlD
Ponatinib—ABCG2—seminal vesicle—urinary bladder cancer	0.000323	0.0049	CbGeAlD
Ponatinib—TEK—lymph node—urinary bladder cancer	0.000307	0.00465	CbGeAlD
Ponatinib—ABL1—vagina—urinary bladder cancer	0.000299	0.00453	CbGeAlD
Ponatinib—PDGFRA—lymph node—urinary bladder cancer	0.000278	0.00421	CbGeAlD
Ponatinib—SRC—lymph node—urinary bladder cancer	0.000273	0.00413	CbGeAlD
Ponatinib—CYP2C8—renal system—urinary bladder cancer	0.000268	0.00406	CbGeAlD
Ponatinib—ABCG2—urethra—urinary bladder cancer	0.000256	0.00388	CbGeAlD
Ponatinib—KDR—lymph node—urinary bladder cancer	0.000251	0.0038	CbGeAlD
Ponatinib—CYP3A5—renal system—urinary bladder cancer	0.000242	0.00366	CbGeAlD
Ponatinib—KIT—lymph node—urinary bladder cancer	0.000222	0.00337	CbGeAlD
Ponatinib—CYP2C8—female reproductive system—urinary bladder cancer	0.000214	0.00325	CbGeAlD
Ponatinib—CYP2C8—vagina—urinary bladder cancer	0.000194	0.00294	CbGeAlD
Ponatinib—ABL1—lymph node—urinary bladder cancer	0.000193	0.00293	CbGeAlD
Ponatinib—ABCG2—vagina—urinary bladder cancer	0.000189	0.00286	CbGeAlD
Ponatinib—ABCB1—prostate gland—urinary bladder cancer	0.000188	0.00286	CbGeAlD
Ponatinib—CYP3A4—renal system—urinary bladder cancer	0.000181	0.00275	CbGeAlD
Ponatinib—CYP2D6—renal system—urinary bladder cancer	0.000178	0.00271	CbGeAlD
Ponatinib—CYP3A5—vagina—urinary bladder cancer	0.000175	0.00265	CbGeAlD
Ponatinib—ABCB1—seminal vesicle—urinary bladder cancer	0.000159	0.00242	CbGeAlD
Ponatinib—CYP3A4—female reproductive system—urinary bladder cancer	0.000145	0.0022	CbGeAlD
Ponatinib—CYP2D6—female reproductive system—urinary bladder cancer	0.000143	0.00217	CbGeAlD
Ponatinib—ABCB1—epithelium—urinary bladder cancer	0.000138	0.0021	CbGeAlD
Ponatinib—ABCB1—renal system—urinary bladder cancer	0.000128	0.00195	CbGeAlD
Ponatinib—ABCB1—urethra—urinary bladder cancer	0.000126	0.00191	CbGeAlD
Ponatinib—ABCG2—lymph node—urinary bladder cancer	0.000122	0.00185	CbGeAlD
Ponatinib—ABL1—Daunorubicin—Epirubicin—urinary bladder cancer	0.000119	0.0395	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Epirubicin—urinary bladder cancer	0.000119	0.0395	CbGdCrCtD
Ponatinib—ABL1—Doxorubicin—Epirubicin—urinary bladder cancer	0.000119	0.0395	CbGdCrCtD
Ponatinib—ABL1—Epirubicin—Doxorubicin—urinary bladder cancer	0.00011	0.0366	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Doxorubicin—urinary bladder cancer	0.00011	0.0366	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—urinary bladder cancer	0.00011	0.0366	CbGdCrCtD
Ponatinib—ABCB1—female reproductive system—urinary bladder cancer	0.000103	0.00156	CbGeAlD
Ponatinib—ABCB1—vagina—urinary bladder cancer	9.3e-05	0.00141	CbGeAlD
Ponatinib—Decreased appetite—Cisplatin—urinary bladder cancer	7.06e-05	0.000686	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—urinary bladder cancer	7.03e-05	0.000683	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—urinary bladder cancer	7.02e-05	0.000683	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	7.01e-05	0.000682	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—urinary bladder cancer	6.99e-05	0.000679	CcSEcCtD
Ponatinib—Infestation—Methotrexate—urinary bladder cancer	6.99e-05	0.000679	CcSEcCtD
Ponatinib—Pancytopenia—Epirubicin—urinary bladder cancer	6.97e-05	0.000677	CcSEcCtD
Ponatinib—Pain—Cisplatin—urinary bladder cancer	6.95e-05	0.000675	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	6.93e-05	0.000673	CcSEcCtD
Ponatinib—Body temperature increased—Gemcitabine—urinary bladder cancer	6.89e-05	0.00067	CcSEcCtD
Ponatinib—Neutropenia—Epirubicin—urinary bladder cancer	6.86e-05	0.000667	CcSEcCtD
Ponatinib—Dizziness—Thiotepa—urinary bladder cancer	6.85e-05	0.000666	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—urinary bladder cancer	6.83e-05	0.000664	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	6.82e-05	0.000663	CcSEcCtD
Ponatinib—Stomatitis—Methotrexate—urinary bladder cancer	6.81e-05	0.000662	CcSEcCtD
Ponatinib—Body temperature increased—Fluorouracil—urinary bladder cancer	6.78e-05	0.000658	CcSEcCtD
Ponatinib—Paraesthesia—Etoposide—urinary bladder cancer	6.68e-05	0.000649	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—urinary bladder cancer	6.66e-05	0.000647	CcSEcCtD
Ponatinib—Weight decreased—Epirubicin—urinary bladder cancer	6.64e-05	0.000645	CcSEcCtD
Ponatinib—Dyspnoea—Etoposide—urinary bladder cancer	6.64e-05	0.000645	CcSEcCtD
Ponatinib—Hyperglycaemia—Epirubicin—urinary bladder cancer	6.62e-05	0.000643	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—urinary bladder cancer	6.61e-05	0.000643	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—urinary bladder cancer	6.61e-05	0.000642	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—urinary bladder cancer	6.59e-05	0.000641	CcSEcCtD
Ponatinib—Vomiting—Thiotepa—urinary bladder cancer	6.59e-05	0.00064	CcSEcCtD
Ponatinib—Pneumonia—Epirubicin—urinary bladder cancer	6.58e-05	0.000639	CcSEcCtD
Ponatinib—Infestation—Epirubicin—urinary bladder cancer	6.54e-05	0.000636	CcSEcCtD
Ponatinib—Infestation NOS—Epirubicin—urinary bladder cancer	6.54e-05	0.000636	CcSEcCtD
Ponatinib—Rash—Thiotepa—urinary bladder cancer	6.53e-05	0.000635	CcSEcCtD
Ponatinib—Dermatitis—Thiotepa—urinary bladder cancer	6.53e-05	0.000634	CcSEcCtD
Ponatinib—Headache—Thiotepa—urinary bladder cancer	6.49e-05	0.000631	CcSEcCtD
Ponatinib—Decreased appetite—Etoposide—urinary bladder cancer	6.47e-05	0.000629	CcSEcCtD
Ponatinib—Pancytopenia—Doxorubicin—urinary bladder cancer	6.45e-05	0.000626	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	6.43e-05	0.000624	CcSEcCtD
Ponatinib—Body temperature increased—Cisplatin—urinary bladder cancer	6.42e-05	0.000624	CcSEcCtD
Ponatinib—Fatigue—Etoposide—urinary bladder cancer	6.42e-05	0.000624	CcSEcCtD
Ponatinib—Neuropathy peripheral—Epirubicin—urinary bladder cancer	6.41e-05	0.000623	CcSEcCtD
Ponatinib—Jaundice—Epirubicin—urinary bladder cancer	6.38e-05	0.00062	CcSEcCtD
Ponatinib—Stomatitis—Epirubicin—urinary bladder cancer	6.38e-05	0.00062	CcSEcCtD
Ponatinib—Constipation—Etoposide—urinary bladder cancer	6.37e-05	0.000619	CcSEcCtD
Ponatinib—Pain—Etoposide—urinary bladder cancer	6.37e-05	0.000619	CcSEcCtD
Ponatinib—Urinary tract infection—Epirubicin—urinary bladder cancer	6.36e-05	0.000618	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—urinary bladder cancer	6.35e-05	0.000617	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	6.31e-05	0.000613	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—urinary bladder cancer	6.31e-05	0.000613	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—urinary bladder cancer	6.28e-05	0.00061	CcSEcCtD
Ponatinib—Asthenia—Gemcitabine—urinary bladder cancer	6.25e-05	0.000608	CcSEcCtD
Ponatinib—Hepatobiliary disease—Epirubicin—urinary bladder cancer	6.19e-05	0.000601	CcSEcCtD
Ponatinib—Epistaxis—Epirubicin—urinary bladder cancer	6.17e-05	0.0006	CcSEcCtD
Ponatinib—Pruritus—Gemcitabine—urinary bladder cancer	6.17e-05	0.000599	CcSEcCtD
Ponatinib—Nausea—Thiotepa—urinary bladder cancer	6.16e-05	0.000598	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—urinary bladder cancer	6.14e-05	0.000597	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—urinary bladder cancer	6.12e-05	0.000595	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—urinary bladder cancer	6.09e-05	0.000592	CcSEcCtD
Ponatinib—Gastrointestinal pain—Etoposide—urinary bladder cancer	6.09e-05	0.000591	CcSEcCtD
Ponatinib—Pruritus—Fluorouracil—urinary bladder cancer	6.06e-05	0.000589	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—urinary bladder cancer	6.05e-05	0.000588	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—urinary bladder cancer	6.05e-05	0.000588	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—urinary bladder cancer	6.05e-05	0.000588	CcSEcCtD
Ponatinib—ABCB1—lymph node—urinary bladder cancer	6.01e-05	0.000912	CbGeAlD
Ponatinib—Diarrhoea—Gemcitabine—urinary bladder cancer	5.96e-05	0.00058	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	5.93e-05	0.000577	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—urinary bladder cancer	5.9e-05	0.000574	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—urinary bladder cancer	5.9e-05	0.000573	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—urinary bladder cancer	5.9e-05	0.000573	CcSEcCtD
Ponatinib—Abdominal pain—Etoposide—urinary bladder cancer	5.88e-05	0.000572	CcSEcCtD
Ponatinib—Body temperature increased—Etoposide—urinary bladder cancer	5.88e-05	0.000572	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—urinary bladder cancer	5.88e-05	0.000572	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—urinary bladder cancer	5.87e-05	0.000571	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—urinary bladder cancer	5.87e-05	0.00057	CcSEcCtD
Ponatinib—Diarrhoea—Fluorouracil—urinary bladder cancer	5.86e-05	0.00057	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—urinary bladder cancer	5.84e-05	0.000568	CcSEcCtD
Ponatinib—Asthenia—Cisplatin—urinary bladder cancer	5.83e-05	0.000566	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—urinary bladder cancer	5.82e-05	0.000566	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—urinary bladder cancer	5.79e-05	0.000562	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—urinary bladder cancer	5.77e-05	0.000561	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	5.73e-05	0.000556	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—urinary bladder cancer	5.71e-05	0.000555	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—urinary bladder cancer	5.69e-05	0.000553	CcSEcCtD
Ponatinib—Dizziness—Fluorouracil—urinary bladder cancer	5.67e-05	0.000551	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—urinary bladder cancer	5.66e-05	0.00055	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—urinary bladder cancer	5.66e-05	0.00055	CcSEcCtD
Ponatinib—Chills—Methotrexate—urinary bladder cancer	5.63e-05	0.000547	CcSEcCtD
Ponatinib—Diarrhoea—Cisplatin—urinary bladder cancer	5.56e-05	0.00054	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—urinary bladder cancer	5.55e-05	0.000539	CcSEcCtD
Ponatinib—Vomiting—Gemcitabine—urinary bladder cancer	5.54e-05	0.000539	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—urinary bladder cancer	5.5e-05	0.000534	CcSEcCtD
Ponatinib—Rash—Gemcitabine—urinary bladder cancer	5.5e-05	0.000534	CcSEcCtD
Ponatinib—Dermatitis—Gemcitabine—urinary bladder cancer	5.49e-05	0.000534	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—urinary bladder cancer	5.49e-05	0.000533	CcSEcCtD
Ponatinib—Erythema—Methotrexate—urinary bladder cancer	5.46e-05	0.000531	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—urinary bladder cancer	5.46e-05	0.000531	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—urinary bladder cancer	5.46e-05	0.000531	CcSEcCtD
Ponatinib—Headache—Gemcitabine—urinary bladder cancer	5.46e-05	0.000531	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—urinary bladder cancer	5.45e-05	0.00053	CcSEcCtD
Ponatinib—Flushing—Epirubicin—urinary bladder cancer	5.45e-05	0.00053	CcSEcCtD
Ponatinib—Vomiting—Fluorouracil—urinary bladder cancer	5.45e-05	0.00053	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—urinary bladder cancer	5.43e-05	0.000528	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—urinary bladder cancer	5.41e-05	0.000525	CcSEcCtD
Ponatinib—Rash—Fluorouracil—urinary bladder cancer	5.4e-05	0.000525	CcSEcCtD
Ponatinib—Dermatitis—Fluorouracil—urinary bladder cancer	5.4e-05	0.000525	CcSEcCtD
Ponatinib—Headache—Fluorouracil—urinary bladder cancer	5.37e-05	0.000522	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—urinary bladder cancer	5.35e-05	0.00052	CcSEcCtD
Ponatinib—Asthenia—Etoposide—urinary bladder cancer	5.34e-05	0.000519	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	5.34e-05	0.000519	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—urinary bladder cancer	5.33e-05	0.000518	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—urinary bladder cancer	5.29e-05	0.000514	CcSEcCtD
Ponatinib—Back pain—Methotrexate—urinary bladder cancer	5.28e-05	0.000513	CcSEcCtD
Ponatinib—Chills—Epirubicin—urinary bladder cancer	5.27e-05	0.000512	CcSEcCtD
Ponatinib—Pruritus—Etoposide—urinary bladder cancer	5.27e-05	0.000512	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—urinary bladder cancer	5.25e-05	0.00051	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—urinary bladder cancer	5.24e-05	0.000509	CcSEcCtD
Ponatinib—Alopecia—Epirubicin—urinary bladder cancer	5.19e-05	0.000504	CcSEcCtD
Ponatinib—Nausea—Gemcitabine—urinary bladder cancer	5.18e-05	0.000503	CcSEcCtD
Ponatinib—Vomiting—Cisplatin—urinary bladder cancer	5.17e-05	0.000502	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—urinary bladder cancer	5.15e-05	0.0005	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—urinary bladder cancer	5.15e-05	0.0005	CcSEcCtD
Ponatinib—Rash—Cisplatin—urinary bladder cancer	5.12e-05	0.000498	CcSEcCtD
Ponatinib—Dermatitis—Cisplatin—urinary bladder cancer	5.12e-05	0.000497	CcSEcCtD
Ponatinib—Erythema—Epirubicin—urinary bladder cancer	5.11e-05	0.000497	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—urinary bladder cancer	5.11e-05	0.000497	CcSEcCtD
Ponatinib—Diarrhoea—Etoposide—urinary bladder cancer	5.09e-05	0.000495	CcSEcCtD
Ponatinib—Nausea—Fluorouracil—urinary bladder cancer	5.09e-05	0.000495	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—urinary bladder cancer	5.08e-05	0.000493	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—urinary bladder cancer	5.05e-05	0.000491	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—urinary bladder cancer	5.04e-05	0.00049	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—urinary bladder cancer	5.04e-05	0.00049	CcSEcCtD
Ponatinib—Back pain—Epirubicin—urinary bladder cancer	4.95e-05	0.000481	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—urinary bladder cancer	4.93e-05	0.000479	CcSEcCtD
Ponatinib—Dizziness—Etoposide—urinary bladder cancer	4.92e-05	0.000478	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—urinary bladder cancer	4.92e-05	0.000478	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	4.9e-05	0.000476	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—urinary bladder cancer	4.89e-05	0.000475	CcSEcCtD
Ponatinib—Chills—Doxorubicin—urinary bladder cancer	4.88e-05	0.000474	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—urinary bladder cancer	4.85e-05	0.000472	CcSEcCtD
Ponatinib—Nausea—Cisplatin—urinary bladder cancer	4.83e-05	0.000469	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—urinary bladder cancer	4.82e-05	0.000468	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—urinary bladder cancer	4.8e-05	0.000467	CcSEcCtD
Ponatinib—Cough—Methotrexate—urinary bladder cancer	4.77e-05	0.000463	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—urinary bladder cancer	4.76e-05	0.000463	CcSEcCtD
Ponatinib—Vomiting—Etoposide—urinary bladder cancer	4.73e-05	0.00046	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—urinary bladder cancer	4.73e-05	0.00046	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—urinary bladder cancer	4.73e-05	0.00046	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—urinary bladder cancer	4.73e-05	0.000459	CcSEcCtD
Ponatinib—Rash—Etoposide—urinary bladder cancer	4.69e-05	0.000456	CcSEcCtD
Ponatinib—Dermatitis—Etoposide—urinary bladder cancer	4.69e-05	0.000456	CcSEcCtD
Ponatinib—Headache—Etoposide—urinary bladder cancer	4.66e-05	0.000453	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—urinary bladder cancer	4.65e-05	0.000452	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—urinary bladder cancer	4.65e-05	0.000452	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.62e-05	0.000449	CcSEcCtD
Ponatinib—Leukopenia—Epirubicin—urinary bladder cancer	4.58e-05	0.000445	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—urinary bladder cancer	4.58e-05	0.000445	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—urinary bladder cancer	4.55e-05	0.000442	CcSEcCtD
Ponatinib—Cough—Epirubicin—urinary bladder cancer	4.46e-05	0.000433	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—urinary bladder cancer	4.46e-05	0.000433	CcSEcCtD
Ponatinib—Infection—Methotrexate—urinary bladder cancer	4.43e-05	0.00043	CcSEcCtD
Ponatinib—Nausea—Etoposide—urinary bladder cancer	4.42e-05	0.00043	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—urinary bladder cancer	4.41e-05	0.000429	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—urinary bladder cancer	4.37e-05	0.000425	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—urinary bladder cancer	4.37e-05	0.000425	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—urinary bladder cancer	4.37e-05	0.000424	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—urinary bladder cancer	4.35e-05	0.000423	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—urinary bladder cancer	4.35e-05	0.000423	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—urinary bladder cancer	4.33e-05	0.000421	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	4.32e-05	0.00042	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—urinary bladder cancer	4.31e-05	0.000419	CcSEcCtD
Ponatinib—Dry mouth—Epirubicin—urinary bladder cancer	4.26e-05	0.000414	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—urinary bladder cancer	4.23e-05	0.000411	CcSEcCtD
Ponatinib—Oedema—Epirubicin—urinary bladder cancer	4.17e-05	0.000405	CcSEcCtD
Ponatinib—Infection—Epirubicin—urinary bladder cancer	4.15e-05	0.000403	CcSEcCtD
Ponatinib—Cough—Doxorubicin—urinary bladder cancer	4.13e-05	0.000401	CcSEcCtD
Ponatinib—Nervous system disorder—Epirubicin—urinary bladder cancer	4.09e-05	0.000398	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—urinary bladder cancer	4.09e-05	0.000397	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—urinary bladder cancer	4.08e-05	0.000397	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	4.06e-05	0.000395	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—urinary bladder cancer	4.05e-05	0.000394	CcSEcCtD
Ponatinib—Hyperhidrosis—Epirubicin—urinary bladder cancer	4.03e-05	0.000392	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—urinary bladder cancer	4.03e-05	0.000392	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—urinary bladder cancer	4.03e-05	0.000391	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—urinary bladder cancer	4.03e-05	0.000391	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—urinary bladder cancer	4e-05	0.000389	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	4e-05	0.000389	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—urinary bladder cancer	3.98e-05	0.000386	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—urinary bladder cancer	3.94e-05	0.000383	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—urinary bladder cancer	3.92e-05	0.000381	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—urinary bladder cancer	3.88e-05	0.000377	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—urinary bladder cancer	3.86e-05	0.000375	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.85e-05	0.000374	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—urinary bladder cancer	3.84e-05	0.000374	CcSEcCtD
Ponatinib—Infection—Doxorubicin—urinary bladder cancer	3.84e-05	0.000373	CcSEcCtD
Ponatinib—Pain—Methotrexate—urinary bladder cancer	3.81e-05	0.00037	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.8e-05	0.000369	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—urinary bladder cancer	3.79e-05	0.000368	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.78e-05	0.000367	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—urinary bladder cancer	3.77e-05	0.000367	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—urinary bladder cancer	3.75e-05	0.000364	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—urinary bladder cancer	3.75e-05	0.000364	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—urinary bladder cancer	3.73e-05	0.000363	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—urinary bladder cancer	3.72e-05	0.000361	CcSEcCtD
Ponatinib—Dyspepsia—Epirubicin—urinary bladder cancer	3.67e-05	0.000357	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.65e-05	0.000354	CcSEcCtD
Ponatinib—Decreased appetite—Epirubicin—urinary bladder cancer	3.63e-05	0.000352	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	3.6e-05	0.00035	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—urinary bladder cancer	3.6e-05	0.00035	CcSEcCtD
Ponatinib—Constipation—Epirubicin—urinary bladder cancer	3.57e-05	0.000347	CcSEcCtD
Ponatinib—Pain—Epirubicin—urinary bladder cancer	3.57e-05	0.000347	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—urinary bladder cancer	3.52e-05	0.000342	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—urinary bladder cancer	3.52e-05	0.000342	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.52e-05	0.000342	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—urinary bladder cancer	3.49e-05	0.000339	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—urinary bladder cancer	3.47e-05	0.000337	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—urinary bladder cancer	3.44e-05	0.000334	CcSEcCtD
Ponatinib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.41e-05	0.000332	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—urinary bladder cancer	3.4e-05	0.00033	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—urinary bladder cancer	3.36e-05	0.000326	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	3.33e-05	0.000324	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—urinary bladder cancer	3.33e-05	0.000323	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—urinary bladder cancer	3.3e-05	0.000321	CcSEcCtD
Ponatinib—Pain—Doxorubicin—urinary bladder cancer	3.3e-05	0.000321	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—urinary bladder cancer	3.3e-05	0.000321	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—urinary bladder cancer	3.3e-05	0.000321	CcSEcCtD
Ponatinib—Asthenia—Methotrexate—urinary bladder cancer	3.2e-05	0.000311	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	3.16e-05	0.000307	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—urinary bladder cancer	3.15e-05	0.000307	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—urinary bladder cancer	3.05e-05	0.000297	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—urinary bladder cancer	3.05e-05	0.000297	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—urinary bladder cancer	3.05e-05	0.000296	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—urinary bladder cancer	2.99e-05	0.000291	CcSEcCtD
Ponatinib—Pruritus—Epirubicin—urinary bladder cancer	2.95e-05	0.000287	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—urinary bladder cancer	2.95e-05	0.000286	CcSEcCtD
Ponatinib—Diarrhoea—Epirubicin—urinary bladder cancer	2.86e-05	0.000277	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—urinary bladder cancer	2.83e-05	0.000275	CcSEcCtD
Ponatinib—Rash—Methotrexate—urinary bladder cancer	2.81e-05	0.000273	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—urinary bladder cancer	2.81e-05	0.000273	CcSEcCtD
Ponatinib—Headache—Methotrexate—urinary bladder cancer	2.79e-05	0.000271	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—urinary bladder cancer	2.77e-05	0.000269	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—urinary bladder cancer	2.76e-05	0.000268	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—urinary bladder cancer	2.73e-05	0.000265	CcSEcCtD
Ponatinib—Vomiting—Epirubicin—urinary bladder cancer	2.65e-05	0.000258	CcSEcCtD
Ponatinib—Nausea—Methotrexate—urinary bladder cancer	2.65e-05	0.000257	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—urinary bladder cancer	2.64e-05	0.000257	CcSEcCtD
Ponatinib—Rash—Epirubicin—urinary bladder cancer	2.63e-05	0.000256	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—urinary bladder cancer	2.63e-05	0.000255	CcSEcCtD
Ponatinib—Headache—Epirubicin—urinary bladder cancer	2.61e-05	0.000254	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—urinary bladder cancer	2.55e-05	0.000248	CcSEcCtD
Ponatinib—Nausea—Epirubicin—urinary bladder cancer	2.48e-05	0.000241	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—urinary bladder cancer	2.45e-05	0.000239	CcSEcCtD
Ponatinib—Rash—Doxorubicin—urinary bladder cancer	2.43e-05	0.000237	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—urinary bladder cancer	2.43e-05	0.000236	CcSEcCtD
Ponatinib—Headache—Doxorubicin—urinary bladder cancer	2.42e-05	0.000235	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—urinary bladder cancer	2.29e-05	0.000223	CcSEcCtD
Ponatinib—LYN—Signaling Pathways—IGF1—urinary bladder cancer	2.9e-06	2.55e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—ERBB2—urinary bladder cancer	2.88e-06	2.53e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—EP300—urinary bladder cancer	2.87e-06	2.53e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HRAS—urinary bladder cancer	2.86e-06	2.51e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.86e-06	2.51e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KRAS—urinary bladder cancer	2.85e-06	2.51e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CXCL8—urinary bladder cancer	2.84e-06	2.5e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KRAS—urinary bladder cancer	2.83e-06	2.49e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MYC—urinary bladder cancer	2.83e-06	2.49e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FGFR3—urinary bladder cancer	2.83e-06	2.49e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL2—urinary bladder cancer	2.83e-06	2.48e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KRAS—urinary bladder cancer	2.82e-06	2.48e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MYC—urinary bladder cancer	2.82e-06	2.48e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTGS2—urinary bladder cancer	2.81e-06	2.47e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KRAS—urinary bladder cancer	2.8e-06	2.46e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ERBB2—urinary bladder cancer	2.79e-06	2.46e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CXCL8—urinary bladder cancer	2.79e-06	2.46e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CREBBP—urinary bladder cancer	2.79e-06	2.45e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ERBB2—urinary bladder cancer	2.79e-06	2.45e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.78e-06	2.44e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.77e-06	2.44e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—EGFR—urinary bladder cancer	2.77e-06	2.43e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ERBB2—urinary bladder cancer	2.76e-06	2.43e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—EGFR—urinary bladder cancer	2.76e-06	2.43e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—KRAS—urinary bladder cancer	2.75e-06	2.42e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—RHOA—urinary bladder cancer	2.75e-06	2.42e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ESR1—urinary bladder cancer	2.75e-06	2.41e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.74e-06	2.4e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.73e-06	2.4e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.73e-06	2.4e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TERT—urinary bladder cancer	2.73e-06	2.4e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL2—urinary bladder cancer	2.72e-06	2.39e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.69e-06	2.37e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MYC—urinary bladder cancer	2.69e-06	2.37e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL2—urinary bladder cancer	2.67e-06	2.35e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CDKN1A—urinary bladder cancer	2.66e-06	2.34e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—PTEN—urinary bladder cancer	2.66e-06	2.34e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RHOA—urinary bladder cancer	2.66e-06	2.33e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CXCL8—urinary bladder cancer	2.65e-06	2.33e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCND1—urinary bladder cancer	2.65e-06	2.33e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.65e-06	2.33e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CXCL8—urinary bladder cancer	2.64e-06	2.32e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HRAS—urinary bladder cancer	2.64e-06	2.32e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—EGFR—urinary bladder cancer	2.64e-06	2.32e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EGFR—urinary bladder cancer	2.63e-06	2.31e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—EGFR—urinary bladder cancer	2.62e-06	2.31e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KRAS—urinary bladder cancer	2.61e-06	2.3e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KRAS—urinary bladder cancer	2.61e-06	2.29e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCND1—urinary bladder cancer	2.6e-06	2.29e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HRAS—urinary bladder cancer	2.58e-06	2.27e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MMP9—urinary bladder cancer	2.57e-06	2.26e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.56e-06	2.25e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CDKN1A—urinary bladder cancer	2.56e-06	2.25e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PTEN—urinary bladder cancer	2.56e-06	2.25e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—ERBB2—urinary bladder cancer	2.55e-06	2.24e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—TYMS—urinary bladder cancer	2.54e-06	2.24e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—urinary bladder cancer	2.54e-06	2.23e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—HRAS—urinary bladder cancer	2.54e-06	2.23e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EP300—urinary bladder cancer	2.54e-06	2.23e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL2—urinary bladder cancer	2.53e-06	2.23e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HRAS—urinary bladder cancer	2.53e-06	2.23e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL2—urinary bladder cancer	2.53e-06	2.22e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MMP9—urinary bladder cancer	2.53e-06	2.22e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CDKN1A—urinary bladder cancer	2.52e-06	2.21e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	2.51e-06	2.21e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	2.51e-06	2.21e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PTEN—urinary bladder cancer	2.51e-06	2.21e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGFR3—urinary bladder cancer	2.5e-06	2.2e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL2—urinary bladder cancer	2.5e-06	2.2e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—urinary bladder cancer	2.49e-06	2.19e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—KRAS—urinary bladder cancer	2.49e-06	2.19e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KRAS—urinary bladder cancer	2.49e-06	2.19e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KRAS—urinary bladder cancer	2.48e-06	2.18e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCND1—urinary bladder cancer	2.47e-06	2.17e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—SRC—urinary bladder cancer	2.47e-06	2.17e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCND1—urinary bladder cancer	2.46e-06	2.17e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CDKN1A—urinary bladder cancer	2.46e-06	2.16e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ERBB2—urinary bladder cancer	2.46e-06	2.16e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTEN—urinary bladder cancer	2.45e-06	2.16e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EP300—urinary bladder cancer	2.44e-06	2.14e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ESR1—urinary bladder cancer	2.43e-06	2.14e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—urinary bladder cancer	2.43e-06	2.13e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GPX1—urinary bladder cancer	2.41e-06	2.12e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CREBBP—urinary bladder cancer	2.41e-06	2.12e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—urinary bladder cancer	2.41e-06	2.11e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—urinary bladder cancer	2.4e-06	2.11e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—urinary bladder cancer	2.4e-06	2.11e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EP300—urinary bladder cancer	2.4e-06	2.11e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—urinary bladder cancer	2.39e-06	2.1e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CDKN1A—urinary bladder cancer	2.39e-06	2.1e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PTEN—urinary bladder cancer	2.38e-06	2.1e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—urinary bladder cancer	2.38e-06	2.1e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	2.38e-06	2.09e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CDKN1A—urinary bladder cancer	2.38e-06	2.09e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PTEN—urinary bladder cancer	2.38e-06	2.09e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IGF1—urinary bladder cancer	2.38e-06	2.09e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—SRC—urinary bladder cancer	2.37e-06	2.08e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	2.36e-06	2.08e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CDKN1A—urinary bladder cancer	2.36e-06	2.07e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.36e-06	2.07e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—PTEN—urinary bladder cancer	2.35e-06	2.07e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—urinary bladder cancer	2.34e-06	2.06e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EP300—urinary bladder cancer	2.34e-06	2.06e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL8—urinary bladder cancer	2.33e-06	2.05e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—SRC—urinary bladder cancer	2.33e-06	2.05e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	2.28e-06	2.01e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—SRC—urinary bladder cancer	2.28e-06	2e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EP300—urinary bladder cancer	2.27e-06	2e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EP300—urinary bladder cancer	2.27e-06	1.99e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.25e-06	1.97e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EP300—urinary bladder cancer	2.24e-06	1.97e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—urinary bladder cancer	2.23e-06	1.96e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—urinary bladder cancer	2.22e-06	1.95e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	2.22e-06	1.95e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—urinary bladder cancer	2.22e-06	1.95e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TYMS—urinary bladder cancer	2.22e-06	1.95e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—urinary bladder cancer	2.21e-06	1.94e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SRC—urinary bladder cancer	2.21e-06	1.94e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SRC—urinary bladder cancer	2.2e-06	1.94e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	2.19e-06	1.92e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	2.19e-06	1.92e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.18e-06	1.92e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.18e-06	1.92e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CDKN1A—urinary bladder cancer	2.18e-06	1.91e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RHOA—urinary bladder cancer	2.18e-06	1.91e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTEN—urinary bladder cancer	2.17e-06	1.91e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—urinary bladder cancer	2.17e-06	1.91e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—urinary bladder cancer	2.16e-06	1.9e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CREBBP—urinary bladder cancer	2.13e-06	1.87e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—urinary bladder cancer	2.13e-06	1.87e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.12e-06	1.86e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—urinary bladder cancer	2.12e-06	1.86e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—urinary bladder cancer	2.11e-06	1.86e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—urinary bladder cancer	2.11e-06	1.85e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—urinary bladder cancer	2.11e-06	1.85e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1—urinary bladder cancer	2.1e-06	1.85e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1A—urinary bladder cancer	2.1e-06	1.85e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GPX1—urinary bladder cancer	2.1e-06	1.84e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTEN—urinary bladder cancer	2.1e-06	1.84e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.09e-06	1.83e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—urinary bladder cancer	2.09e-06	1.83e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—urinary bladder cancer	2.08e-06	1.83e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—urinary bladder cancer	2.08e-06	1.83e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EP300—urinary bladder cancer	2.07e-06	1.82e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.06e-06	1.81e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.06e-06	1.81e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	2.06e-06	1.81e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—urinary bladder cancer	2.04e-06	1.79e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—urinary bladder cancer	2.04e-06	1.79e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—urinary bladder cancer	2.04e-06	1.79e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—urinary bladder cancer	2.02e-06	1.77e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EP300—urinary bladder cancer	2e-06	1.76e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	2e-06	1.76e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—urinary bladder cancer	2e-06	1.75e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.99e-06	1.75e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—urinary bladder cancer	1.98e-06	1.74e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.98e-06	1.74e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—urinary bladder cancer	1.98e-06	1.74e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—urinary bladder cancer	1.96e-06	1.73e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SRC—urinary bladder cancer	1.94e-06	1.71e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.94e-06	1.71e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—urinary bladder cancer	1.94e-06	1.7e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.94e-06	1.7e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—urinary bladder cancer	1.93e-06	1.7e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—urinary bladder cancer	1.93e-06	1.7e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RHOA—urinary bladder cancer	1.93e-06	1.69e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—urinary bladder cancer	1.91e-06	1.68e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—urinary bladder cancer	1.91e-06	1.68e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—EP300—urinary bladder cancer	1.9e-06	1.67e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—urinary bladder cancer	1.88e-06	1.66e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—urinary bladder cancer	1.83e-06	1.61e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—urinary bladder cancer	1.83e-06	1.61e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—urinary bladder cancer	1.83e-06	1.6e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.82e-06	1.6e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—urinary bladder cancer	1.81e-06	1.59e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—urinary bladder cancer	1.81e-06	1.59e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.8e-06	1.58e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—urinary bladder cancer	1.78e-06	1.57e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—urinary bladder cancer	1.78e-06	1.57e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—urinary bladder cancer	1.77e-06	1.55e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.76e-06	1.55e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—urinary bladder cancer	1.75e-06	1.53e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—urinary bladder cancer	1.74e-06	1.53e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—urinary bladder cancer	1.74e-06	1.53e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.73e-06	1.52e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—urinary bladder cancer	1.73e-06	1.52e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1A—urinary bladder cancer	1.72e-06	1.51e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTEN—urinary bladder cancer	1.72e-06	1.51e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—urinary bladder cancer	1.71e-06	1.51e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—urinary bladder cancer	1.7e-06	1.5e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—urinary bladder cancer	1.69e-06	1.49e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—urinary bladder cancer	1.67e-06	1.47e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—urinary bladder cancer	1.67e-06	1.47e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—urinary bladder cancer	1.64e-06	1.44e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EP300—urinary bladder cancer	1.64e-06	1.44e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.64e-06	1.44e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—urinary bladder cancer	1.63e-06	1.43e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—urinary bladder cancer	1.62e-06	1.43e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—urinary bladder cancer	1.62e-06	1.42e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—urinary bladder cancer	1.61e-06	1.42e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—urinary bladder cancer	1.6e-06	1.41e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SRC—urinary bladder cancer	1.59e-06	1.4e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—urinary bladder cancer	1.58e-06	1.39e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.57e-06	1.38e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—urinary bladder cancer	1.56e-06	1.37e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—urinary bladder cancer	1.55e-06	1.36e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—urinary bladder cancer	1.54e-06	1.35e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—urinary bladder cancer	1.53e-06	1.35e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1A—urinary bladder cancer	1.53e-06	1.34e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTEN—urinary bladder cancer	1.52e-06	1.34e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.51e-06	1.33e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.48e-06	1.3e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.47e-06	1.29e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EP300—urinary bladder cancer	1.45e-06	1.28e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—urinary bladder cancer	1.43e-06	1.26e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—urinary bladder cancer	1.43e-06	1.26e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.43e-06	1.25e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.42e-06	1.25e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—urinary bladder cancer	1.42e-06	1.25e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.42e-06	1.25e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—urinary bladder cancer	1.4e-06	1.23e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—urinary bladder cancer	1.37e-06	1.2e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.36e-06	1.2e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.36e-06	1.2e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.35e-06	1.19e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.35e-06	1.19e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—urinary bladder cancer	1.32e-06	1.16e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.29e-06	1.14e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.27e-06	1.11e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—urinary bladder cancer	1.26e-06	1.11e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—urinary bladder cancer	1.24e-06	1.09e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.24e-06	1.09e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.23e-06	1.09e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.19e-06	1.05e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.18e-06	1.04e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—urinary bladder cancer	1.17e-06	1.03e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—urinary bladder cancer	1.17e-06	1.03e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.16e-06	1.02e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—urinary bladder cancer	1.12e-06	9.86e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.08e-06	9.46e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—urinary bladder cancer	1.04e-06	9.13e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—EP300—urinary bladder cancer	1.03e-06	9.02e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.01e-06	8.92e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—urinary bladder cancer	9.93e-07	8.73e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—EP300—urinary bladder cancer	9.68e-07	8.5e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.67e-07	8.5e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	9.29e-07	8.16e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.61e-07	6.69e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.63e-07	5.83e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.33e-07	5.56e-06	CbGpPWpGaD
